Efficacy and safety of sodium RISedronate for glucocorticoid-induced OsTeoporosis with rheumaTOid arthritis (RISOTTO study): A multicentre, double-blind, randomized, placebo-controlled trial

No evidence has shown the efficacy of Sodium Risedronate (Risedronate) for glucocorticoid-induced osteoporosis (GIO) in patients with Rheumatoid arthritis (RA). The aim of this study was to explore the effectiveness and safety of Risedronate for GIO complicated with RA. This was a six-month randomiz...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Fujieda, Yuichiro, Horita, Tetsuya, Nishimoto, Naoki, Tanimura, Kazuhide, Amasaki, Yoshiharu, Kasahara, Hideki, Furukawa, Shin, Takeda, Tsuyoshi, Fukaya, Shinji, Matsui, Kazuo, Tsutsumi, Akito, Furusaki, Akira, Sagawa, Akira, Katayama, Kou, Takeuchi, Kaoru, Katsumata, Kazuaki, Kurita, Takashi, Shane, Peter, Kato, Masaru, Oku, Kenji, Yasuda, Shinsuke, Takahata, Masahiko, Iwasaki, Norimasa, Atsumi, Tatsuya
Format: Dataset
Sprache:eng
Schlagworte:
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:No evidence has shown the efficacy of Sodium Risedronate (Risedronate) for glucocorticoid-induced osteoporosis (GIO) in patients with Rheumatoid arthritis (RA). The aim of this study was to explore the effectiveness and safety of Risedronate for GIO complicated with RA. This was a six-month randomized, double-blind, placebo-controlled trial of 95 patients with GIO complicated with RA from 19 centers. The primary endpoint was the change from baseline in lumbar spine bone mineral density (L-BMD). Secondary endpoints included changes in femoral neck and total hip BMD and bone turnover markers, as well as rheumatoid arthritis Disease Activity Score with 28-joint counts. Incident of non-traumatic spine fractures and adverse events were tracked as safety endpoints. Increase in L-BMD was significantly greater in the Risedronate group compared to the Placebo group (Risedronate: 3.49% [95% CI: 1.92–5.05] vs Placebo: 0.12% [95% CI: −2.07 to 2.30], p Risedronate was effective in increasing L-BMD and was well tolerated in patients with GIO complicated with RA.
DOI:10.6084/m9.figshare.13041891